Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Scotiabank analyst George Farmer downgraded Tempest Therapeutics (TPST) to Sector Perform from Outperform with a reverse stock-split adjusted ...

The Merkel cell carcinoma market is poised for steady growth, with a strong CAGR projected from 2024 to 2034. This expansion across the 7MM will be driven by the launch of innovative therapies ...

DelveInsight's Merkel Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment practices, Merkel cell carcinoma emerging drugs, market share of individual ...

Investors are nervous. As of 9:55 a.m. ET Wednesday morning, shares of Roche Holding ( RHHBY -2.81%) are down 2.3%, Eli Lilly ( LLY -4.38%) stock is off 3.2%, and AstraZeneca ( AZN -4.87%) is doing ...

Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a price ...

From Phoenix to Dallas, the league passed on Doncic – now a generational star – and is still paying the price.

The report forecasts global market growth from $116.1 billion in 2024 to $168 billion by 2029 at a CAGR of 7.7%. Highlighting advances in immunotherapy, CAR-T cell therapy, and biomarker-based ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

The backlash continues in car showrooms as growing protests against Musk’s government role hit his electric empire hard.

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.